Physician profile
John J Lee
NPI 1710048160
$1,816.59
in general payments reported to CMS, 2019-2025
10 companies · $87.33 in 2025
The $87.33 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $50.09 · 2021: $55.31 · 2022: $49.53 · 2023: $34.02 · 2024: $1,368 · 2025: $87.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,198 · Food and Beverage: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,197.93 |
| Food and Beverage | $291.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $1,197.93 | 2024 | |
| Novo Nordisk INC | $401.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $50.09 | 2020 | |
| Janssen Pharmaceuticals, INC | $45.28 | 2021-2022 | |
| Glaxosmithkline, LLC. | $29.94 | 2021-2024 | Shingrix |
| Astrazeneca Pharmaceuticals LP | $23.58 | 2019 | |
| Stryker Corporation | $20.13 | 2023 | |
| Novartis Pharmaceuticals Corporation | $20.12 | 2019 | |
| Lundbeck LLC | $14.39 | 2024 | Rexulti |
| Medtronic, INC. | $13.89 | 2023 | Vanta Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.